# Fostamatinib for Hospitalized Adults With COVID-19

> **NCT04579393** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 59 (actual)

## Conditions studied

- Coronavirus Disease 2019

## Interventions

- **DRUG:** Placebo
- **DRUG:** fostamatinib

## Key facts

- **NCT ID:** NCT04579393
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-08
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04579393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04579393, "Fostamatinib for Hospitalized Adults With COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04579393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*